Description
CABOZANTITINB
First action · last action
2016-10-04 · 2017-03-17
Transactions
2
First transaction's obligation
$165,000
Base + all options value (sum of deltas)
$13,750
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797D60634
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 2 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2016-10-04+$165,000= $165,000
- Mod P000012017-03-17-$151,250= $13,750
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2016-10-04 | +$165,000 | $165,000 | CABOZANTITINB |
| Mod P00001· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE | 2017-03-17 | −$151,250 | $13,750 | CABOZANTITINB |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI R47FPKTS9T63)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36F79722D0147 | NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2022 |
| VA26117F0396 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $76,355 | FY2017 |
| VA26117F0347 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $6,925 | FY2017 |
| VA26117F0102 | 261-NETWORK CONTRACT OFFICE 21 (36C261) · 6505 · DRUGS AND BIOLOGICALS | $6,925 | FY2017 |
| VA25817J0101 | 258-NETWORK CNTRCT OFF 22G (36C258) · 6505 · DRUGS AND BIOLOGICALS | $6,875 | FY2017 |
| VA797P16A0025 | NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2016 |
Other recipients under 6505 from 618-MINNEAPOLIS VA MED CTR (00618) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C26318K0032 | MCKESSON CORPORATION | 618-MINNEAPOLIS VA MED CTR (00618) | $49,039,589 | FY2017 |
| VA26317E0866 | MCKESSON CORPORATION | 618-MINNEAPOLIS VA MED CTR (00618) | $8,564,037 | FY2017 |
| VA26317E0865 | MCKESSON CORPORATION | 618-MINNEAPOLIS VA MED CTR (00618) | $9,473,612 | FY2017 |
| VA26317E0576 | MCKESSON CORPORATION | 618-MINNEAPOLIS VA MED CTR (00618) | $7,019,930 | FY2017 |
| VA26317E0575 | MCKESSON CORPORATION | 618-MINNEAPOLIS VA MED CTR (00618) | $7,912,337 | FY2017 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA26317J0003_3600_V797D60634_3600 · retrieved 2026-09-26.